Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $500K | $102M | $119M | $141M | $214M | $398M | $492M | $589M |
| Revenue growth | — | — | — | 20361.2% | 16.4% | 18.3% | 52.1% | 85.9% | 23.5% | 19.8% |
| Operating income | -$19.3M | -$18.7M | -$35.3M | $31.8M | $41.3M | $52.4M | $102M | $86.8M | $195M | $258M |
| Operating margin | — | — | -7059.0% | 31.1% | 34.7% | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Net income | -$18.1M | -$18.4M | -$34.0M | $31.9M | $75.0M | $39.5M | $83.1M | $71.4M | $164M | $214M |
| Net margin | — | — | -6800.7% | 31.2% | 63.0% | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| EPS (diluted) | -$0.22 | -$0.21 | -$0.33 | $0.30 | $0.71 | $0.37 | $0.75 | $0.63 | $1.31 | $1.68 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.0M | -$13.7M | -$26.1M | $34.6M | $45.0M | $60.4M | $116M | $144M | $240M | $209M |
| Capital expenditures | $96.1K | — | $92.0K | $19.0K | $11.0K | $1.02M | $29.0K | $231K | $556K | $58.0K |
| Free cash flow | -$18.1M | — | -$26.2M | $34.6M | $45.0M | $59.4M | $116M | $143M | $239M | $209M |
| Share buybacks | — | — | — | — | — | $12.1M | $6.91M | $0.00 | $0.00 | $25.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $13.9M | $57.5M | $16.6M | $89.5M | $130M | $171M | $298M | $138M | $518M | $709M |
| Total assets | $41.7M | $85.4M | $60.4M | $112M | $192M | $238M | $376M | $470M | $851M | $1.10B |
| Total liabilities | $2.40M | $4.42M | $9.67M | $24.7M | $22.8M | $31.0M | $75.2M | $82.2M | $124M | $150M |
| Shareholders' equity | $39.3M | $81.0M | $50.8M | $87.6M | $170M | $207M | $300M | $388M | $728M | $954M |
| Retained earnings | -$108M | -$127M | -$161M | -$129M | -$53.7M | -$26.3M | $49.9M | $121M | $285M | $474M |
| Shares (wtd avg diluted) | 83.0M | 103M | 103M | 106M | 106M | 108M | 111M | 114M | 125M | 127M |
Every figure is extracted from CATALYST PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.